Allergan files anti-CGRP migraine drug in the US
US regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine.
Read More
Tag: ubrogepant
Allergan to file ubrogepant for migraine early next year
Allergan is gearing up to file its oral CGRP receptor ubrogepant in the US for the treatment of migraine, following the success and completion of two safety studies.
Read More
Trial success for Allergan’s anti-CGRP migraine drug
The first of two pivotal Phase III clinical trials evaluating Allergan’s experimental anti-CGRP migraine drug ubrogepant has met its key goal.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
